Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Expands bioprocessing footprint across Asia
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Awards highlight Avantor's commitment to the Biopharma industry
Subscribe To Our Newsletter & Stay Updated
